Evicenter
MarkdownMedical informationP&T meetings
Lanifibranor (IVA337)

Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis

Manufacturer
Inventiva
Last updated
220 sources

Product information and disease descriptionPlace of product in therapyDisease description

Diagnosis

22 evidence topics · 13 sources

Primary risk assessment with FIB-4: thresholds, AASLD 2023 practice guidance

“When the fibrosis-4 index (FIB-4) is <1.3, patients can be followed in the primary care setting and reassessed periodically.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“In patients older than age 65, a FIB-4 cutoff of > 2.0 should be used. FIB-4 has low accuracy in those under age 35; thus, secondary assessment should be considered in those <35 with increased metabolic risk or elevated liver chemistries.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“In patients with FIB4 ≥ 1.3, a secondary assessment should be done [preferentially vibration-controlled elastography (VCTE) or Enhanced Liver Fibrosis (ELF) initially] or the patient referred for further risk stratification (if being seen in a nongastroenterology/hepatology setting). Direct referral to gastroenterology/hepatology should be considered in those with aminotransferases persistently (> 6 mo) above normal to exclude other causes of liver disease or when FIB4 > 2.67 due to the increased risk of clinically significant fibrosis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“In addition, a change in FIB-4 status category from low risk (< 1.3) to intermediate risk (1.3–2.67) to high risk (> 2.67) may be used to assess clinical progression.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

Screening with FIB-4 in type 2 diabetes or prediabetes: ADA Standards of Care 2026

“4.22a Screen adults with type 2 diabetes or with prediabetes, particularly those with obesity or other cardiometabolic risk factors or established cardiovascular disease, for their risk of having or developing cirrhosis related to metabolic dysfunction–associated steatohepatitis (MASH) using a calculated fibrosis-4 index (FIB-4)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“4.23 Adults with type 2 diabetes or prediabetes with a FIB-4 ≥ 1.3 should have additional risk stratification by liver stiffness measurement with transient elastography, or, if unavailable, the enhanced liver fibrosis (ELF) test. B” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“A value of <1.3 is considered low risk of having advanced fibrosis (F3–F4) and for developing adverse liver outcomes, while ≥1.3 is considered as having a higher probability of at-risk MASH clinically significant fibrosis (≥F2) and increased risk of adverse liver outcomes. A value of >2.67 confers a high risk of having advanced fibrosis (F3–F4), and referral to the liver specialist is warranted without additional testing.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“In individuals with diabetes ≥65 years of age, higher cutoffs for FIB-4 have been recommended (1.9–2.0 rather than ≥1.3)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

Rule-out and rule-in cut-offs of non-invasive tests for fibrosis and at-risk MASH, EASL-EASD-EASO 2024 guideline
Selection of resmetirom candidates with non-invasive tests: AASLD 2024 guidance update

“There are no FDA-approved noninvasive tests to diagnose MASH with F2-F3 or to monitor response to pharmacotherapy.” (opens the source at this quote in a new tab)

“Notably, the FDA-approved label does not require liver biopsy to confirm the diagnosis of fibrotic MASH. While MASH can only be definitively diagnosed by histologic examination, patient selection in practice is based on evidence of steatosis and fibrosis as determined by NILDA methodologies among persons with cardiometabolic risk factors without other causes of steatosis, notably alcohol consumption of more than 20 g/d for women and more than 30 g/d for men.” (opens the source at this quote in a new tab)

“In general, imaging-based NILDAs, such as liver stiffness measurement (LSM) by vibration-controlled transient elastography (VCTE) or magnetic resonance elastography (MRE),” (opens the source at this quote in a new tab)

“In the MAESTRO-NASH trial, participants were screened with VCTE and those with LSM >8.5 kPa in whom liver histology demonstrated MASH with F2-F3 were enrolled. Among enrolled participants, the median (interquartile range) LSM by VCTE was 12 kPa (10-15 kPa) and the mean LSM by MRE was 3.5 kPa. The median (interquartile range) of the enhanced liver fibrosis score was 9.7 (9.2-10.4).” (opens the source at this quote in a new tab)

“For example, 50% of participants with biopsy-proven F2-F3 in the MAESTRO-NASH trial had LSM by VCTE that was outside the interquartile range of 10 kPa to 15 kPa.” (opens the source at this quote in a new tab)

Selection of semaglutide candidates with non-invasive tests: AASLD 2025 guidance update

“Semaglutide (Wegovy) candidates should have MASH with stages 2–3 fibrosis, identified using non-invasive tests (NITs) such as VCTE (8–15 kPa), MRE (3.1–4.4 kPa), or ELF (9.2–10.5), rather than liver biopsy, which is impractical and unnecessary for most patients. In those with VCTE (15–20 kPa), MRE (4.4–5 kPa), or ELF (10.5–11.3), an individualized decision to treat should be based on exclusion of cirrhosis with another confirmatory NIT, or cross-sectional imaging excluding nodular-appearing liver contour and signs of portal hypertension, or a platelet count of <150,000/mm3.” (opens the source at this quote in a new tab)

“Semaglutide is not approved as an indication for patients with MASH cirrhosis (VCTE >20 kPa, MRE >5.0 kPa, ELF >11.3, and/or evidence of portal hypertension).” (opens the source at this quote in a new tab)

“A FIB-4 score below 1.3 excludes advanced fibrosis (F3 or greater) in 99% of all patients and 95% of patients with multiple cardiometabolic risks in the primary care setting.” (opens the source at this quote in a new tab)

“To be clear, FIB-4 should not be used as a single rule-in or rule-out test for semaglutide eligibility for patients with MASLD/MASH.” (opens the source at this quote in a new tab)

“The recommended range of 8–15 kPa included ~50% of the study population, while up to 19% of participants had LSM <8 kPa, and up to 32.5% of participants had LSM ≥15 kPa.” (opens the source at this quote in a new tab)